REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Cvs S.A.S. Centro de Vacunas Speices (Colombia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Cvs S.A.S. Centro de Vacunas Speices Profile Updated: December 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Cvs S.A.S. Centro de Vacunas Speices is based in Colombia. The head office is in Bucaramanga. The enterprise currently operates in the Drugs and Druggists' Sundries Merchant Wholesalers sector. It was first established on April 12, 2011. From the latest financial highlights, Cvs S.A.S. Centro de Vacunas Speices reported a net sales revenue increase of 46.52% in 2023. Its’ total assets recorded a growth of 67.83%. The enterprise’s net profit margin increased by 2.04% in 2023.

Headquarters
Calle 17 # 30-52
Bucaramanga; Santander;

Contact Details: Purchase the Cvs S.A.S. Centro de Vacunas Speices report to view the information.

Basic Information
Outstanding Shares:
Purchase the Cvs S.A.S. Centro de Vacunas Speices report to view the information.
Incorporation Date:
April 12, 2011
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Member of the Board of Directors
Purchase this report to view the information.
Fiscal Inspector
Company Performance
Financial values in the chart are available after Cvs S.A.S. Centro de Vacunas Speices report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency COP. Absolute financial data is included in the purchased report.
Net sales revenue
46.52%▲
Total operating revenue
45.84%▲
Operating profit (EBIT)
119.26%▲
EBITDA
117.38%▲
Net Profit (Loss) for the Period
137.96%▲
Total assets
67.83%▲
Total equity
62.72%▲
Operating Profit Margin (ROS)
2.9%▲
Net Profit Margin
2.04%▲
Return on Equity (ROE)
19.6%▲
Quick Ratio
-0.31%▼
Cash Ratio
-0.53%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo